{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:23Z","timestamp":1790155703087,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.ymgme.2008.03.003","type":"journal-article","created":{"date-parts":[[2008,4,19]],"date-time":"2008-04-19T13:31:26Z","timestamp":1208611886000},"page":"319-325","source":"Crossref","is-referenced-by-count":109,"title":["Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3"],"prefix":"10.1016","volume":"94","author":[{"given":"Anouk C.","family":"Vedder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Breunig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma E.","family":"Donker-Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Winchester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ineke J.M.","family":"Ten Berge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna E.M.","family":"Groener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.F.G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2008.03.003_bib1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/clinchem\/13.7.565","article-title":"Enzymatic abnormalities in diseases of sphingolipid metabolism","volume":"13","author":"Brady","year":"1967","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2008.03.003_bib2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","article-title":"Fabry\u2019s disease: alpha-galactosidase deficiency","volume":"167","author":"Kint","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2008.03.003_bib3","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/jmg.33.8.682","article-title":"Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene","volume":"33","author":"Redonnet-Vernhet","year":"1996","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2008.03.003_bib4","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","volume":"vol. 3","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ymgme.2008.03.003_bib5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2008.03.003_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2008.03.003_bib7","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2008.03.003_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2008.03.003_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2008.03.003_bib10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2008.03.003_bib11","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2008.03.003_bib12","first-page":"307","article-title":"Cellular and tissue distribution of intravenously administered agalsidase alfa","author":"Murray","year":"2006","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2008.03.003_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2008.03.003_bib14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2008.03.003_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease\u2014role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2008.03.003_bib16","unstructured":"FDA briefing document Fabrazyme, 2002. Available from: <http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3917B1_03_FDA%20backgrounder.pdf>."},{"key":"10.1016\/j.ymgme.2008.03.003_bib17","unstructured":"FDA briefing report Replagal, 2002. Available from: <http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3917B2_02_FDA-Backgrounder.pdf>."},{"key":"10.1016\/j.ymgme.2008.03.003_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy","author":"Ohashi","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2008.03.003_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ymgme.2006.04.013","article-title":"Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy","volume":"89","author":"Vedder","year":"2006","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2008.03.003_bib20","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S0149-2918(02)80075-3","article-title":"Immunogenicity of therapeutic proteins: clinical implications and future prospects","volume":"24","author":"Schellekens","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymgme.2008.03.003_bib21","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2516.2003.00781.x","article-title":"Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymgme.2008.03.003_bib22","first-page":"157","article-title":"Fabry\u2019s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes","volume":"81","author":"Desnick","year":"1973","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.ymgme.2008.03.003_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","article-title":"Differential assay for lysosomal \u03b1-galactosidases in human tissues and its application to Fabry\u2019s disease","volume":"112","author":"Mayes","year":"1981","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2008.03.003_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10545-005-5263-4","article-title":"Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease","volume":"28","author":"Mills","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2008.03.003_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2008.03.003_bib26","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1373\/clinchem.2006.079012","article-title":"HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma","volume":"53","author":"Groener","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2008.03.003_bib27","doi-asserted-by":"crossref","first-page":"40911","DOI":"10.1074\/jbc.M301804200","article-title":"Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase","author":"Aguilera","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2008.03.003_bib28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cca.2007.02.042","article-title":"Monitoring of Gaucher patients with a novel chitotriosidase assay","volume":"381","author":"Schoonhoven","year":"2007","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2008.03.003_bib29","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0002-9149(87)91133-7","article-title":"Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study","volume":"59","author":"Levy","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2008.03.003_bib30","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1373\/clinchem.2004.037937","article-title":"Immunoquantification of {alpha}-galactosidase: evaluation for the diagnosis of Fabry disease","volume":"50","author":"Fuller","year":"2004","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2008.03.003_bib31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/13543784.11.6.851","article-title":"Agalsidase alfa\u2014a preparation for enzyme replacement therapy in Anderson\u2013Fabry disease","volume":"11","author":"Beck","year":"2002","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ymgme.2008.03.003_bib32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(01)05816-0","article-title":"Enzyme-replacement therapy for Anderson\u2013Fabry disease","volume":"358","author":"Pastores","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2008.03.003_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/345309","article-title":"Recombinant enzyme therapy for Fabry disease. Absence of editing of human \u03b1-galactosidase A mRNA","volume":"72","author":"Blom","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2008.03.003_bib34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2008.03.003_bib35","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J. Hum. Genet."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719208000772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719208000772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T15:16:55Z","timestamp":1588605415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719208000772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S1096719208000772"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2008.03.003","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}